Examkin

Question

Difficulty: Very hardPharmacologic Interventions

A 62-year-old female is evaluated in the inpatient dermatology consultation service for exquisitely painful, violaceous, and necrotic skin lesions on her bilateral thighs and lower abdomen that have rapidly progressed over the past two weeks. She has a history of end-stage renal disease secondary to diabetic nephropathy and receives hemodialysis three times weekly. She also has a history of permanent atrial fibrillation and diet-controlled type 2 diabetes mellitus. Her current medications include calcium acetate, calcitriol, warfarin, and metoprolol succinate. Vital signs are within normal limits. Physical examination reveals retiform purpura with central areas of black eschar and surrounding indurated erythema on the proximal lower extremities and adiposity-rich areas of the abdomen. The lesions are extremely tender to palpation. Peripheral pulses are intact. Laboratory evaluation shows:

Serum calcium: 10.2 mg/dL10.2 \text{ mg/dL}
Serum phosphorus: 7.8 mg/dL7.8 \text{ mg/dL}
Intact parathyroid hormone (PTH): 850 pg/mL850 \text{ pg/mL}
International Normalized Ratio (INR): 2.42.4

A punch biopsy of the lesion margin demonstrates microvascular calcification, extensive intimal fibroplasia, and cutaneous ischemia without evidence of systemic vasculitis. Which of the following sets of pharmacologic interventions is most appropriate for the management of this patient's dermatologic condition?

  1. A
    Initiate intravenous pamidronate, substitute calcium acetate with aluminum hydroxide, and maintain current warfarin therapy
  2. B
    Initiate oral cinacalcet, maintain calcitriol therapy, and transition warfarin to subcutaneous enoxaparin
  3. Initiate intravenous sodium thiosulfate, substitute calcium acetate with sevelamer, and transition warfarin to apixabanAnswer
  4. D
    Initiate intravenous methylprednisolone, substitute calcium acetate with sevelamer, and transition warfarin to dabigatran
  5. E
    Initiate intravenous sodium thiosulfate, substitute calcium acetate with sevelamer, and maintain current warfarin therapy

Answer

The most appropriate management is to initiate intravenous sodium thiosulfate, substitute calcium acetate with sevelamer, and transition warfarin to apixaban.
The correct combination directly addresses the three pillars of calciphylaxis management in this patient: active treatment, calcium-phosphorus product reduction, and removal of iatrogenic triggers. Intravenous sodium thiosulfate acts as a calcium chelator and antioxidant to promote lesion healing. Calcium acetate must be stopped because it contributes to an unacceptably high calcium-phosphorus product (>55 mg2/dL2> 55 \text{ mg}^2\text{/dL}^2 is high risk); it should be replaced with a non-calcium, non-aluminum binder like sevelamer. Finally, warfarin is a notorious trigger for calciphylaxis because it inhibits the vitamin K-dependent activation of Matrix Gla Protein, a critical defense against vascular calcification. Since the patient requires ongoing anticoagulation for atrial fibrillation, switching to apixaban is appropriate, as it does not inhibit MGP and has an established safety profile in hemodialysis patients.

Step-by-Step Solution

1
Diagnose the primary dermatologic condition based on clinical and biopsy findings.
The patient has calciphylaxis (calcific uremic arteriolopathy).
The presentation of exquisitely painful retiform purpura with necrotic eschars in an end-stage renal disease (ESRD) patient, combined with a high calcium-phosphorus product (10.2×7.8=79.56 mg2/dL210.2 \times 7.8 = 79.56 \text{ mg}^2\text{/dL}^2) and biopsy showing microvascular calcification without vasculitis, is pathognomonic.
2
Identify current medications that are exacerbating the condition.
Calcium acetate, calcitriol, and warfarin must be discontinued.
Calcium acetate and calcitriol actively increase the serum calcium and phosphorus burden. Warfarin acts as a direct molecular trigger for calciphylaxis by inhibiting the vitamin K-dependent carboxylation of Matrix Gla Protein (MGP), an essential endogenous inhibitor of tissue calcification.
3
Select the appropriate pharmacologic substitutions and targeted therapies.
Use sodium thiosulfate, sevelamer, and apixaban.
Intravenous sodium thiosulfate is a potent antioxidant and vasodilator that increases the solubility of calcium deposits. Sevelamer provides necessary phosphate binding without adding a calcium load. Apixaban provides required systemic anticoagulation for atrial fibrillation with established safety and FDA approval for patients on hemodialysis, unlike dabigatran, rivaroxaban, or enoxaparin.

Key Concept

Successful management of calciphylaxis in ESRD requires initiating intravenous sodium thiosulfate, aggressively lowering the calcium-phosphorus product (avoiding calcium-based binders and active vitamin D), and discontinuing warfarin, which actively promotes vascular calcification via inhibition of Matrix Gla Protein.
Rate this question

Topics

Pharmacologic Interventions

More questions from this topic